- Home
- ENTX vs LPSN Comparison
ENTX vs LPSN Comparison
Compare ENTX & LPSN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ENTX
- LPSN
- Stock Information
- Founded
- ENTX 2010
- LPSN 1995
- Country
- ENTX Israel
- LPSN United States
- Employees
- ENTX 21
- LPSN N/A
- Industry
- ENTX Biotechnology: Biological Products (No Diagnostic Substances)
- LPSN EDP Services
- Sector
- ENTX Health Care
- LPSN Technology
- Exchange
- ENTX Nasdaq
- LPSN Nasdaq
- Market Cap
- ENTX 82.2M
- LPSN 93.7M
- IPO Year
- ENTX 2018
- LPSN 2000
- Fundamental
- Price
- ENTX $1.85
- LPSN $0.88
- Analyst Decision
- ENTX Strong Buy
- LPSN Hold
- Analyst Count
- ENTX 1
- LPSN 1
- Target Price
- ENTX $10.00
- LPSN N/A
- AVG Volume (30 Days)
- ENTX 76.7K
- LPSN 1.9M
- Earning Date
- ENTX 11-07-2025
- LPSN 11-06-2025
- Dividend Yield
- ENTX N/A
- LPSN N/A
- EPS Growth
- ENTX N/A
- LPSN N/A
- EPS
- ENTX N/A
- LPSN N/A
- Revenue
- ENTX $166,000.00
- LPSN $271,750,000.00
- Revenue This Year
- ENTX N/A
- LPSN N/A
- Revenue Next Year
- ENTX N/A
- LPSN N/A
- P/E Ratio
- ENTX N/A
- LPSN N/A
- Revenue Growth
- ENTX 191.23
- LPSN N/A
- 52 Week Low
- ENTX $1.50
- LPSN $0.61
- 52 Week High
- ENTX $2.79
- LPSN $2.08
- Technical
- Relative Strength Index (RSI)
- ENTX 42.76
- LPSN 42.23
- Support Level
- ENTX $1.83
- LPSN $0.91
- Resistance Level
- ENTX $2.22
- LPSN $1.01
- Average True Range (ATR)
- ENTX 0.11
- LPSN 0.06
- MACD
- ENTX -0.02
- LPSN -0.01
- Stochastic Oscillator
- ENTX 9.52
- LPSN 23.75
About ENTX Entera Bio Ltd.
Entera Bio Ltd is a clinical-stage biopharmaceutical company engaged in the development of orally delivered macromolecule therapeutics, including peptides and therapeutic proteins. The company focuses on underserved, chronic medical conditions where oral administration of a mini tablet peptide or peptide replacement therapy has the potential to significantly shift a treatment paradigm. Its product candidates are; EB613 for the treatment of osteoporosis and EB612 for the treatment of hypoparathyroidism are first-in-class mini tablet formulations of synthetic human PTH (1-34) (teriparatide), designed to have differing pharmacokinetic, or PK, profiles.
About LPSN LivePerson Inc.
LivePerson Inc is the enterprise leader in digital customer conversation. The Conversational Cloud, the Company's enterprise-class digital customer conversation platform, is trusted by the world's top brands to accelerate their contact center transformation, orchestrate conversations across all channels, departments, and systems, increase agent productivity, and deliver more personalized, AI-empowered customer experiences. The company has a presence in the United Kingdom, Asia-Pacific, Latin America, and Europe.